Abivax SA American Depositary Shares (ABVX) - Total Liabilities
Based on the latest financial reports, Abivax SA American Depositary Shares (ABVX) has total liabilities worth $117.55 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore ABVX shareholders equity momentum to track the company's year-over-year net asset growth rate.
Abivax SA American Depositary Shares - Total Liabilities Trend (2013–2025)
This chart illustrates how Abivax SA American Depositary Shares's total liabilities have evolved over time, based on quarterly financial data.
Abivax SA American Depositary Shares Competitors by Total Liabilities
The table below lists competitors of Abivax SA American Depositary Shares ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Assurant Inc
NYSE:AIZ
|
USA | $30.42 Billion |
|
LG Corp
KO:003550
|
Korea | ₩3.65 Trillion |
|
Orkla ASA
OL:ORK
|
Norway | Nkr40.03 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $2.38 Billion |
|
Hyundai Rotem Co
KO:064350
|
Korea | ₩3.64 Trillion |
|
China Spacesat Co Ltd
SHG:600118
|
China | CN¥5.25 Billion |
|
Mowi ASA
OL:MOWI
|
Norway | Nkr5.86 Billion |
|
Industrial Bank Of Korea
KO:024110
|
Korea | ₩463.84 Trillion |
Liability Composition Analysis (2013–2025)
This chart breaks down Abivax SA American Depositary Shares's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Abivax SA American Depositary Shares market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.25 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.27 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.21 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Abivax SA American Depositary Shares's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Abivax SA American Depositary Shares (2013–2025)
The table below shows the annual total liabilities of Abivax SA American Depositary Shares from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $129.08 Million | -21.60% |
| 2024-12-31 | $164.64 Million | +25.63% |
| 2023-12-31 | $131.05 Million | +91.72% |
| 2022-12-31 | $68.36 Million | -17.94% |
| 2021-12-31 | $83.30 Million | +55.99% |
| 2020-12-31 | $53.40 Million | +61.15% |
| 2019-12-31 | $33.14 Million | +70.87% |
| 2018-12-31 | $19.39 Million | +244.15% |
| 2017-12-31 | $5.63 Million | +45.23% |
| 2016-12-31 | $3.88 Million | -13.78% |
| 2015-12-31 | $4.50 Million | +11.64% |
| 2014-12-31 | $4.03 Million | -9.29% |
| 2013-12-31 | $4.44 Million | -- |
About Abivax SA American Depositary Shares
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials f… Read more